Vaxcyte receives FDA clearance of IND application for VAX-31

Vaxcyte announced that the U.S. Food and Drug Administration has cleared the Company’s adult Investigational New Drug application for VAX-31, a 31-valent pneumococcal conjugate vaccine candidate designed to prevent invasive pneumococcal disease. Vaxcyte expects to initiate the VAX-31 Phase 1/2 clinical study in adults in the fourth quarter of this year and announce topline safety, tolerability and immunogenicity results in the second half of 2024.